Results 131 to 140 of about 827,025 (271)
Mass Spectrometry Reviews, EarlyView.ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley +1 more source
Targeting β-catenin: PROTACs and precision degraders for Wnt-driven cancers
Frontiers in OncologyThe Wnt signaling pathway, a highly conserved molecular cascade, orchestrates critical biological processes including embryonic development, cell differentiation, and proliferation across diverse organisms.
Jonathan Trapani +7 more
doaj +1 more source
Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer
Medicinal Research Reviews, EarlyView.ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek +3 more
wiley +1 more source
Recent advances in targeting protein degradation for tumor immunotherapy
Journal of Hematology & OncologyImmunotherapy has revolutionized the landscape of cancer treatment, yet its efficacy is often limited by drug resistance, the immunosuppressive tumor microenvironment (TME), and the “undruggable” nature of key immunoregulatory proteins.
Shuai Li +4 more
doaj +1 more source
PharmaceuticalsBackground/Objectives: Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional small molecules that induce ubiquitin–proteasome–mediated degradation of target proteins and have matured from proof-of-concept chemistry to a clinically validated ...
Ganglin Su, Yihan Wang, Lin Yao
doaj +1 more source
Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
ChemMedChemAbstractBreast cancer (BC) accounts for 30 % of cancer cases among women cancer patients globally, indicating the urgent need for the development of selective therapies targeting BCs. Recently, proteolysis‐targeting chimera (PROTAC) has emerged as a promising strategy to target breast cancer. PROTAC is a chimeric molecule consisting of a target protein
Yerim Jin, Yeongju Lee
openaire +2 more sources
Molecular Glue Degraders in Early Development for Cancer Therapy
Medicinal Research Reviews, EarlyView.ABSTRACT Molecular glue degraders are an emerging class of small molecule allosteric modulators that induce or stabilize protein‐protein interactions, enabling targeted degradation of previously intractable proteins. By redirecting E3 ligases to recognize neosubstrates, proteins that are not typically recognized by a specific E3 ubiquitin ligase, they ...
E. Sila Ozdemir +4 more
wiley +1 more source
Innovation in pest management: can the past inform the future?
Pest Management Science, EarlyView.Progress in pest management occurred incrementally, but occasionally, transformative discoveries introduced disruptive technologies. Looking ahead, generative artificial intelligence is expected to accelerate agricultural discovery by integrating vast datasets from mechanization, genetics, and chemistry.
Eric Moog, Franck E. Dayan
wiley +1 more source
BMC BiologyBackground Proteolysis targeting chimera (PROTAC), a novel drug discovery strategy, utilizes the ubiquitin–proteasome system to degrade target proteins in cells.
Shuai Meng +8 more
doaj +1 more source
Responsive Materials, EarlyView.Peptide‐based antibacterial nanoplatforms, encompassing self‐assembled peptides and peptide‐engineered inorganic, polymeric, and lipid nanocarriers, are systematically reviewed. The article highlights design principles and stimuli‐responsive regulation for improving peptide stability, delivery efficiency, and antibacterial performance.
Peng Tan +8 more
wiley +1 more source